CellProtect is a novel drug candidate for treatment of multiple myeloma. It is based on autologous NK cells that are expanded and their cytotoxic activity restored through a patented process. The cells are then infused into the patient to treat the disease. CellProtect is currently  investigated in a Phase I clinical trial in multiple myeloma patients at the Karolinska University Hospital in Huddinge, Sweden.

CellProtect has experimental support from animal models and ex vivo studies where CellProtect has been shown to kill multiple myeloma cells. CellProtec will be used as an adjunct treatment to an autologous stem cell transplant, which is the standard of care for patients that are eligible for a transplant. The goal is to prolong time to remission without affecting quality of life for the patient, although CellProtect also could have a potential to cure multiple myeloma.

CellProtect has a unique mechanism of action different from the treatment regiments currently used. Considering the nature of CellProtect as an autologous cell therapy product it may be used as adjunct therapy to current clinical praxis and in combination with other therapies to expand the treatment options for an improved effect, a more stringent complete response, and curative potential.

CPNP has been granted Orphan Drug Designation for the treatment of MM from the EC and are planning to advance the clinical development and reach the market via accelerated/conditional approval

CellProtect is manufactured under GMP conditions at the core facility KCC, Vecura at the Karolinska University Hospital. The CellProtect  candidate drug product has 48 months documented stability at frozen conditions.